918797-27-0

Upstream product

• 918797-41-8 {(S)-5-((S)-2-benzyloxycarbonylamino-4-methylpentanoylamino)-5-[4-(6-methoxyquinolin-8-ylamino)pentylcarbamoyl]pentyl}carbamic acid tert-butyl ester 
• 918797-36-1 4-(4-(((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)carbamoyl)phenoxy)benzoic acid benzyl ester 
• 918797-33-8 (2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxo-heptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamic acid tert-butyl ester 
• 100002-49-1 4(S)-t-butoxycarbonylamino-N-butyl-3(S)-hydroxy-6-methylheptanamide 
• 918797-35-0 4-(4-(benzyloxycarbonyl)phenoxy)benzoic acid 
• 58521-45-2 tert-butoxycarbonyl-L-leucinal 
• 67010-43-9 (3S,4S)-ethyl 4-(tert-butoxycarbonylamino)-3-hydroxy-6-methylheptanoate 
• 58521-49-6 (3S,4S)-4-(tert-butoxycarbonylamino)-3-hydroxy-6-methylheptanoic acid 
• 2215-89-6 oxybis(benzoic acid) 
• 2018-66-8 Z-Leu-OH 

Relevant academic research and scientific papers

Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'

Statine-based inhibitors of Plasmepsin II (PLMII) coupled with Primaquine have been designed using the 'double-drug' approach. The IC50 values for PLMII inhibition ranged from 0.59 to 400nM and the best IC50 value for inhibition of P

High antiplasmodial activity of novel plasmepsins I and II inhibitors

The aim of this study was to develop new antiplasmodial compounds acting through distinct mechanisms during both the liver and the blood stages of the parasite life cycle. Compounds were designed on the basis of the "double-drug" approach: primaquine, whi